Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-12
2005-07-12
Henley, III, Raymond (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S475000
Reexamination Certificate
active
06916843
ABSTRACT:
Epoxyeicosatrienoic acids (EETs) are products of cytocrome P450 epoxygenases that have vasodilatory properties similar to endotheilum-derived hyperpolarizing factor (EDHF). The cytochrome P450 isoform CYP2J2 was cloned and identified as a source of EETs in human endothelial cells. Physiological concentrations of EETs or overexpression of CYP2J2 decreased cytolcine-induced endothelial cell adhesion molecule expression and prevented subsequent leukocyte adhesion to the vascular wall by a mechanism involving inhibition of transcription factor NF-κB and IκB kinase (IKK). The inhibitory effects of EETs were independent of their membrane hyporpolarizing effects suggesting that these molecules play an important non-vasodilatory role in vascular inflammation.
REFERENCES:
patent: 5102670 (1992-04-01), Abraham et al.
patent: 5334736 (1994-08-01), Sun et al.
patent: 5593990 (1997-01-01), D'Amato
patent: 5834293 (1998-11-01), Capdevila et al.
patent: 5925375 (1999-07-01), Lenk et al.
patent: 5955496 (1999-09-01), Hammock et al.
patent: WO 94/01139 (1994-01-01), None
patent: WO 98/06261 (1998-02-01), None
patent: WO 99/05299 (1999-02-01), None
Node et al., Journal of the American College of Cardiology, Feb. 1999, vol. 33, No. 2 Suppl. A, pp. 2A.
Ala et al., 37 Agents & Actions. 134-139 (1992).
Biegelsen et al., 10 Coron. Artery Dis. 241-56 (1999).
Blanc et al., 19 Liver 42-49 (1999).
Brown et al., 68 Methods in Enzymology 109-151 (1979).
Campbell et al., 78 Circ. Res. 415-423 (1996).
Casey & Seabra, 271 J. Biol. Chem. 5289-92 (1996).
Chen et al. 274(8) J. Biol. Chem. 4764-9(1999).
Corey et al., 102 J. Am. Chem. Soc. 1433-1435 (1980).
DeCaterina et al., 96 J. Clin. Invest. 60-68 (1995).
Dzau et al., 18(SuppIIII) Hypertension. 1II115-III121 (1991).
Falck et al., 25 Tetrahedron Lett. 1755-1756 (1982).
Gething & Sambrook, 293 Nature 620-625 (1981).
Giraldez et al., 272 J. Biol. Chem. 21420-21426 (1997).
Green et al., 126 Anal. Biochem. 131-138 (1982).
Gyllenhammar et al., 97 J. Immunol. Methods. 209-213 (1987).
Hess et al., 25 Stroke. 1463-1467 (1994).
International Search Report, issued Oct. 13, 2000.
Lefer et al., 33 Annu. Rev. Pharmacol. Toxicol 71-90 (1993).
Li et al., 41 Cardiovasc. Res. 109-115 (1999).
Liao et al., 44 Clin. Chem. 1799-1808 (1998).
Marti et al., 156 Am. J. Pathol. 965-976 (2000).
Mathews et al., 16 Free Radic. Biol. Med. 763-70 (1994).
May & Ghosh, 284(5412) Science 271-3 (1999).
Mehta et al., 257 Am. J. Physiol. H1240-H1246 (1989).
Mehta et al., 5 J. Myocard. Ischemia. 31-41 (1993).
Merrifield, 85 J. Amer. Chem. Soc. 2149-2154 (1963).
Meyer et al., 12 Can. J. Cardiol. 930-934 (1996).
Miyake et al., 114 J. Cell Biol. 557-565 (1991).
Morisseau et al., 96 Proc. Natl. Acad. Sci. USA 8849-8854 (1999).
Morrow & Roberts, 300 Methods Enzymol. 3-12 (1999).
Morrow et al., 87 Proc. Natl. Acad. Sci. USA 9383-9387 (1990).
Node et al., 285 Science 1276-1279 (1999).
Oltman et al., 83 Circ. Res. 932-939 (1998).
Oltman et al., Database BIOSIS Accession No. 515821.
Palombella et al., 78 Cell 773-785 (1994).
Ramos et al., 84 Circ. Res. 1237-1244 (1999).
Reilly et al., 96 Circulation. 3314-3320 (1997).
Rosolowsky et al., 1299 Biochim. Biophys. Acta. 267 (1996).
Russell et al., 278 Am. J. Physiol. Gastrointest. Liver Physiol. G878-G885 (2000).
Samarasinghe et al., 24 Heptatology. 1230-1237 (1996).
Scarborough et al., 31(1) Drug Metab Rev. 205-34.
Schweer et al., 32 J. Mass Spectrom. 1362-1370 (1997).
Shin et al., 271 J. Biol. Chem. 271: 11317-11324 (1996).
Stemmer et al., 164 Gene. 49-53 (1995).
Tan et al., 17 Eur. J. Vasc. Endovasc. Surg. 373-89 (1999).
VanRollins et al., 34 J. Lipid Res. 1931-1942 (1993).
Wu et al., 271 (7) J. Biol. Chem. 3460-8 (1996).
Wu, et al., 272 J. Biol. Chem. 12551-9 (1997).
Yang et al., 274 Am. J. Physiol. H1955-H1961 (1998).
Yang et al., 83 Circ. Res. 552-559 (1998).
Yu et al., 57(5) Mol. Pharmacol. 1011-20 (2000).
Zeldin et al., 50(5) Mol. Pharmacol 1111-7 (1996).
Zeldin et al., 51 Mol. Pharm. 931-943 (1997).
Liao James K.
Zeldin Darryl
Delacroix-Muirheid C.
Henley III Raymond
Klarquist & Sparkman, LLP
The United States of America as represented by the Department of
LandOfFree
Anti-inflammatory actions of cytochrome P450... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-inflammatory actions of cytochrome P450..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-inflammatory actions of cytochrome P450... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3416216